Core Viewpoint - A class action has been filed against Perrigo Company, alleging that the company misled investors about the value of its infant formula during the specified class period [1] Company Overview - Perrigo Company (NYSE: PRGO) provides over-the-counter health and wellness solutions in the U.S., Europe, and internationally [1] Class Action Details - The class period for the action is from February 27, 2024, to November 4, 2025 [1] - The lawsuit is on behalf of all investors who acquired Perrigo securities during this class period [1]

Core Viewpoint - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, with specific allegations of misleading statements and undisclosed risks impacting their financial performance [1]. Company Summaries Freeport-McMoRan Inc. (NYSE: FCX) - Class Period: February 15, 2022 – September 24, 2025 - Allegations include failure to ensure safety at the Grasberg Block Cave mine, leading to heightened risks of worker fatalities and undisclosed regulatory and reputational risks [2]. Perrigo Company plc (NYSE: PRGO) - Class Period: February 27, 2023 – November 4, 2025 - Allegations focus on significant underinvestment in the infant formula business acquired from Nestlé, requiring substantial capital expenditures for remediation, and overstated financial results [3]. Jayud Global Logistics Limited (NASDAQ: JYD) - Class Period: April 21, 2023 – April 30, 2025 - Allegations include involvement in a fraudulent stock promotion scheme, insider trading activities, and misleading public statements regarding the company's operations and risks [4]. StubHub Holdings, Inc. (NYSE: STUB) - Class Period: September 14, 2025 – November 24, 2025 - Allegations pertain to changes in vendor payment timing adversely affecting free cash flow, leading to materially misleading financial reports [5].

Core Viewpoint - A class action securities lawsuit has been filed against Perrigo Company plc, alleging securities fraud that affected investors between February 27, 2023, and November 4, 2025 [1] Group 1: Allegations of Fraud - The lawsuit claims that Perrigo's infant formula business, acquired from Nestlé, suffered from significant underinvestment in maintenance and operational improvements [2] - It is alleged that Perrigo needed to make substantial capital and operational expenditures beyond previously stated cost estimates to remediate issues in the infant formula business [2] - The complaint states that there were significant manufacturing deficiencies in the facility for the infant formula business [2] - As a result of these issues, Perrigo's financial results, including earnings and cash flow, were overstated [2] - The positive statements made by the defendants regarding the Company's business and prospects were materially misleading and lacked a reasonable basis [2] Group 2: Legal Process and Participation - Investors who suffered losses during the relevant time frame have until January 16, 2026, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4]

Core Viewpoint - A class action securities lawsuit has been filed against Perrigo Company plc, alleging securities fraud that affected investors between February 27, 2023, and November 4, 2025 [1] Group 1: Allegations of Fraud - The lawsuit claims that Perrigo's acquisition of the infant formula business from Nestlé was significantly underinvested in maintenance and operational improvements [2] - It is alleged that Perrigo needed to incur substantial capital and operational expenditures beyond previously stated cost estimates to address issues in the infant formula business [2] - The complaint states that there were significant manufacturing deficiencies in the facility related to the infant formula business [2] - As a result of these issues, Perrigo's financial results, including earnings and cash flow, were overstated [2] - The positive statements made by the defendants regarding the Company's business and prospects were materially misleading and lacked a reasonable basis [2] Group 2: Legal Process and Participation - Investors who suffered losses during the relevant time frame have until January 16, 2026, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff to share in any potential recovery [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has a strong track record in high-stakes securities litigation [4] - The firm has over 70 employees dedicated to serving clients and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Perrigo Company plc regarding a class action lawsuit alleging that the company made materially false and misleading statements about its infant formula business and its financial results during the specified class period [1]. Group 1: Allegations - The complaint alleges that the infant formula business acquired from Nestlé suffered from significant underinvestment in maintenance, operational improvements, and repairs [1]. - Perrigo needed to make substantial capital and operational expenditures beyond the company's stated cost estimates to remediate the infant formula business [1]. - There were significant manufacturing deficiencies in the facility for the company's infant formula business [1]. - As a result of the aforementioned issues, the company's financial results, including earnings and cash flow, were overstated [1]. - The defendants' positive statements about the company's business, operations, and prospects were materially misleading and lacked a reasonable basis [1]. Group 2: Class Action Details - The class period for the lawsuit is from February 27, 2023, to November 4, 2025 [1]. - Shareholders are encouraged to register for the class action by January 16, 2026, to potentially be appointed as lead plaintiff [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive status updates throughout the lifecycle of the case [2].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Perrigo Company plc regarding a class action lawsuit due to alleged misleading statements and operational deficiencies related to the company's infant formula business [1][3]. Group 1: Allegations - The complaint alleges that during the class period from February 27, 2023, to November 4, 2025, Perrigo issued materially false and misleading statements [3]. - Specific allegations include significant underinvestment in the infant formula business acquired from Nestlé, necessitating substantial capital and operational expenditures beyond stated cost estimates [3]. - The complaint also highlights significant manufacturing deficiencies in the infant formula facility, leading to overstated financial results, including earnings and cash flow [3]. Group 2: Class Action Details - Shareholders who purchased PRGO shares during the specified class period are encouraged to register for the class action, with a deadline of January 16, 2026, to seek lead plaintiff status [4]. - Registration allows shareholders to receive updates throughout the lifecycle of the case, with no cost or obligation to participate [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that artificially inflated stock prices [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Perrigo Company plc securities between February 27, 2023, and November 4, 2025, of the January 16, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Perrigo securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by January 16, 2026, to serve as lead plaintiff [2] - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business, which suffered from underinvestment and significant manufacturing deficiencies [4] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [3] - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [3]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Perrigo Company plc regarding a class action lawsuit alleging that the company made materially false and misleading statements about its infant formula business and its financial results during the specified class period [1]. Allegations - The complaint claims that the infant formula business acquired from Nestlé suffered from significant underinvestment in maintenance, operational improvements, and repairs [1]. - Perrigo is alleged to have needed to make substantial capital and operational expenditures beyond the company's stated cost estimates to remediate the infant formula business [1]. - There were significant manufacturing deficiencies identified in the facility for the infant formula business [1]. - As a result of these issues, the company's financial results, including earnings and cash flow, were overstated [1]. - The positive statements made by the defendants regarding the company's business, operations, and prospects were materially misleading and lacked a reasonable basis [1]. Class Action Details - The class period for the lawsuit is from February 27, 2023, to November 4, 2025 [1]. - Shareholders are encouraged to register for the class action by January 16, 2026, to potentially be appointed as lead plaintiffs [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who incurred losses due to misleading statements or omissions [3].

Core Viewpoint - The Perrigo Company plc is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the financial health of its infant formula business acquired from Nestlé [1][3]. Summary by Sections Class Action Lawsuit Details - The class action lawsuit is titled French v. Perrigo Company plc and covers securities purchases made between February 27, 2023, and November 4, 2025 [1]. - Investors have until January 16, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. Allegations Against Perrigo - The lawsuit alleges that Perrigo's acquisition of Nestlé's Gateway infant formula plant was plagued by significant underinvestment and operational deficiencies [3]. - Specific claims include the need for substantial capital expenditures beyond initial estimates to address these issues, leading to overstated financial results [3]. Financial Impact and Stock Performance - On February 27, 2024, Perrigo disclosed acquisition-related charges of $35 million to $45 million for remediation efforts, resulting in a 50% decline in earnings per share compared to the previous year [4]. - Following this announcement, Perrigo's stock price fell over 15% [4]. - On May 7, 2024, Perrigo reported net sales of $91 million, a decrease of 34.5%, and a gross margin decline of 90 basis points, leading to a nearly 10% drop in stock price [5]. - On August 6, 2025, Perrigo's adjusted gross profit decreased by $30 million (6.9%), with a reported gross margin of 34.4%, causing an 11% decline in stock price [6]. - On November 5, 2025, Perrigo announced a strategic review of its infant formula business and slashed its fiscal year 2025 outlook, resulting in a stock price drop of over 25% [7]. Company Background - Perrigo provides over-the-counter health and wellness solutions and has been involved in significant acquisitions to expand its product offerings [2].

Core Insights - During market turbulence, investors often seek dividend-yielding stocks, which typically have high free cash flows and offer substantial dividends [1] Group 1: Perrigo Company PLC (NYSE:PRGO) - Dividend Yield: 8.83% [6] - Canaccord Genuity analyst Susan Anderson maintained a Buy rating but reduced the price target from $40 to $20 on Nov. 6, 2025, with an accuracy rate of 62% [6] - JP Morgan analyst Chris Scott downgraded the stock from Overweight to Neutral, cutting the price target from $32 to $20 on Nov. 6, 2025, with an accuracy rate of 65% [6] - Recent News: Perrigo reported mixed Q3 financial results and lowered its FY25 adjusted EPS guidance below estimates [6] Group 2: Bristol-Myers Squibb Co (NYSE:BMY) - Dividend Yield: 4.81% [6] - Morgan Stanley analyst Terence Flynn maintained an Underweight rating and reduced the price target from $37 to $36 on Dec. 12, 2025, with an accuracy rate of 69% [6] - Guggenheim analyst Seamus Fernandez upgraded the stock from Neutral to Buy, setting a price target of $62 on Dec. 12, 2025, with an accuracy rate of 81% [6] - Recent News: Bristol Myers Squibb received FDA Priority Review for Opdivo Plus AVD combination sBLA in untreated stage III/IV cHL [6] Group 3: CVS Health Corp (NYSE:CVS) - Dividend Yield: 3.35% [6] - Truist Securities analyst David Macdonald maintained a Buy rating and raised the price target from $95 to $98 on Dec. 10, 2025, with an accuracy rate of 67% [6] - UBS analyst Kevin Caliendo maintained a Buy rating and increased the price target from $96 to $97 on Dec. 10, 2025, with an accuracy rate of 65% [6] - Recent News: CVS raised its FY2025 adjusted EPS and sales guidance [6]